kabutan

Heartseed announces phase 1/2 trial results for allogeneic iPS cell-derived cardiac spheroid HS-001

Mon Jun 1, 2026 4:02 pm JST Catalyst

Heartseed Inc. <219A> announced after the close on Monday positive results from its Phase 1/2 LAPiS trial evaluating HS-001, an allogeneic iPS cell-derived cardiac spheroid under development for severe heart failure associated with ischemic heart disease. The study met its primary safety endpoint, with no issues identified that would impact plans for regulatory submission. Furthermore, secondary endpoints demonstrated efficacy across multiple metrics, providing strong support for a regulatory filing. Based on these outcomes, Heartseed aims to apply for manufacturing and marketing approval by the end of 2026.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.

Related Articles